WO2019219851A1 - Compositions for inducing an immune response - Google Patents

Compositions for inducing an immune response Download PDF

Info

Publication number
WO2019219851A1
WO2019219851A1 PCT/EP2019/062694 EP2019062694W WO2019219851A1 WO 2019219851 A1 WO2019219851 A1 WO 2019219851A1 EP 2019062694 W EP2019062694 W EP 2019062694W WO 2019219851 A1 WO2019219851 A1 WO 2019219851A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
administered
cell
dose
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2019/062694
Other languages
English (en)
French (fr)
Inventor
Adrian VS HILL
Irina Redchenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020207036057A priority Critical patent/KR102810080B1/ko
Priority to SG11202010862VA priority patent/SG11202010862VA/en
Priority to JP2020561892A priority patent/JP2021528367A/ja
Priority to CA3097951A priority patent/CA3097951A1/en
Priority to CN202411963750.9A priority patent/CN119770632A/zh
Priority to EP19734251.2A priority patent/EP3793581A1/en
Priority to US17/055,056 priority patent/US12246038B2/en
Priority to MX2020012150A priority patent/MX2020012150A/es
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to AU2019270424A priority patent/AU2019270424A1/en
Priority to CN201980030633.8A priority patent/CN112088012A/zh
Publication of WO2019219851A1 publication Critical patent/WO2019219851A1/en
Anticipated expiration legal-status Critical
Priority to JP2024078396A priority patent/JP2024105526A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Definitions

  • Prostate cancer is the most common non-skin cancer and the second leading cause of cancer deaths in men. Approximately 1.1 million men were diagnosed with this disease globally in 2012 thus accounting for 15% of all cancer diagnoses in men. More than 70% of cases of prostate cancer occur in the developed world. For example, in the USA alone in 2014 an estimated 233,000 men were diagnosed with this disease and approximately 30,000 deaths were predicted (Siegel et al (2014). CA Cancer J Clin 64:9-29). While there have been significant advances in prostate cancer treatment, there are few treatments available for advanced stages of the disease and these have demonstrated unsatisfactory effectiveness. Therefore, development of effective therapies remains a high priority for treatment of this disease.
  • the 5T4 antigen polypeptide has the amino acid sequence provided in SEQ ID NO:l.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
PCT/EP2019/062694 2018-05-16 2019-05-16 Compositions for inducing an immune response Ceased WO2019219851A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US17/055,056 US12246038B2 (en) 2018-05-16 2019-05-16 Compositions for inducing an immune response
JP2020561892A JP2021528367A (ja) 2018-05-16 2019-05-16 免疫応答を誘導するための組成物
CA3097951A CA3097951A1 (en) 2018-05-16 2019-05-16 Compositions for inducing an immune response
CN202411963750.9A CN119770632A (zh) 2018-05-16 2019-05-16 诱导免疫应答的组合物和方法
EP19734251.2A EP3793581A1 (en) 2018-05-16 2019-05-16 Compositions for inducing an immune response
KR1020207036057A KR102810080B1 (ko) 2018-05-16 2019-05-16 면역 반응을 유도하기 위한 조성물
CN201980030633.8A CN112088012A (zh) 2018-05-16 2019-05-16 诱导免疫应答的组合物和方法
MX2020012150A MX2020012150A (es) 2018-05-16 2019-05-16 Composiciones para inducir una respuesta inmunitaria.
AU2019270424A AU2019270424A1 (en) 2018-05-16 2019-05-16 Compositions for inducing an immune response
SG11202010862VA SG11202010862VA (en) 2018-05-16 2019-05-16 Compositions for inducing an immune response
JP2024078396A JP2024105526A (ja) 2018-05-16 2024-05-14 免疫応答を誘導するための組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1807932.7A GB201807932D0 (en) 2018-05-16 2018-05-16 Compositions and methods for inducing an immune response
GB1807932.7 2018-05-16

Publications (1)

Publication Number Publication Date
WO2019219851A1 true WO2019219851A1 (en) 2019-11-21

Family

ID=62623405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/062694 Ceased WO2019219851A1 (en) 2018-05-16 2019-05-16 Compositions for inducing an immune response

Country Status (11)

Country Link
US (1) US12246038B2 (https=)
EP (1) EP3793581A1 (https=)
JP (2) JP2021528367A (https=)
KR (1) KR102810080B1 (https=)
CN (2) CN112088012A (https=)
AU (1) AU2019270424A1 (https=)
CA (1) CA3097951A1 (https=)
GB (1) GB201807932D0 (https=)
MX (1) MX2020012150A (https=)
SG (1) SG11202010862VA (https=)
WO (1) WO2019219851A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023105221A1 (en) * 2021-12-07 2023-06-15 Vaccitech (Uk) Limited Vaccine boost methods and compositions
US11793843B2 (en) 2019-01-10 2023-10-24 Janssen Biotech, Inc. Prostate neoantigens and their uses
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011128704A1 (en) 2010-04-16 2011-10-20 Isis Innovation Limited Poxvirus expression system
WO2014063832A1 (en) * 2012-10-28 2014-05-01 Bavarian Nordig A/S Pr13.5 promoter for robust t-cell and antibody responses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011128704A1 (en) 2010-04-16 2011-10-20 Isis Innovation Limited Poxvirus expression system
WO2014063832A1 (en) * 2012-10-28 2014-05-01 Bavarian Nordig A/S Pr13.5 promoter for robust t-cell and antibody responses

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
"NCBI", Database accession no. NM_006670.4
AL-TAEI ET AL., LUNG CANCER, vol. 77, 2012, pages 312 - 318
AMATOSTEPANKIW, FUTURE ONCOL., vol. 8, 2012, pages 231 - 237
ANTROBUS ET AL., J AM SOC GENE THERAPY., vol. 22, 2014, pages 668 - 674
BORTHWICK ET AL., MOL THER., vol. 22, 2014, pages 464 - 475
CAPPUCCINI ET AL., ONCOTARGET, vol. 8, no. 29, 2017, pages 47474 - 47489
CHALLISSTAM, ACTA ONCOL., vol. 29, 1990, pages 545 - 550
EWER ET AL., NAT COMMUN., vol. 4, 2013, pages 2836
EWER ET AL., NEW ENGL J MED., vol. 374, 2016, pages 1635 - 1646
HARROP ET AL., CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 61, 2012, pages 2283 - 2294
HARROP ET AL., CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 62, no. 9, 2014, pages 1511 - 1520
HARROP ET AL.: "however, vaccine-specific cellular immune responses and clinical efficacy were modest", J IMMUNOTHERAPY, vol. 33, 2010, pages 999 - 1005
HODGSON ET AL., J INF DIS., vol. 211, 2015, pages 1076 - 1086
KIM ET AL., HUMAN VACCINES, vol. 6, 2010, pages 784 - 791
RICHARD HARROP ET AL: "Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial", CANCER IMMUNOLOGY, IMMUNOTHERAPY, NIH AUTHOR MANUSCRIPT, vol. 62, no. 9, 23 July 2013 (2013-07-23), Berlin/Heidelberg, pages 1511 - 1520, XP055620513, ISSN: 0340-7004, DOI: 10.1007/s00262-013-1457-z *
SIEGEL ET AL., CA CANCER J CLIN, vol. 64, 2014, pages 9 - 29
SOUTHALL ET AL., BR J CANCER, vol. 61, 1990, pages 89 - 95
SOUTHALL ET AL., BR J CANCER., vol. 61, 1990, pages 89 - 95
STARZYNSKA ET AL., BR J CANCER, vol. 69, 1994, pages 899 - 902
STERN ET AL., SEMINARS IN CANCER BIOLOGY, vol. 29, 2014, pages 13 - 20
STERNHARROP, CANCER IMMUNOLOGY, IMMUNOTHERAPY, 2016, pages 1 - 12
SWADLING ET AL., SCIENCE TRANSLATIONAL MEDICINE., vol. 6, 2014, pages 261ra153
TORITSE ORUBU ET AL: "Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA", PLOS ONE, vol. 7, no. 6, 27 June 2012 (2012-06-27), pages e40167, XP055075345, DOI: 10.1371/journal.pone.0040167 *
ZHANG ET AL., N ENGL J MED., vol. 348, 2003, pages 203 - 213

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11793843B2 (en) 2019-01-10 2023-10-24 Janssen Biotech, Inc. Prostate neoantigens and their uses
US12582683B2 (en) 2019-01-10 2026-03-24 Janssen Biotech, Inc. Prostate neoantigens and their uses
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023105221A1 (en) * 2021-12-07 2023-06-15 Vaccitech (Uk) Limited Vaccine boost methods and compositions

Also Published As

Publication number Publication date
KR102810080B1 (ko) 2025-05-21
SG11202010862VA (en) 2020-11-27
JP2021528367A (ja) 2021-10-21
GB201807932D0 (en) 2018-06-27
EP3793581A1 (en) 2021-03-24
AU2019270424A1 (en) 2020-11-19
MX2020012150A (es) 2021-04-28
US20210213060A1 (en) 2021-07-15
CA3097951A1 (en) 2019-11-21
CN112088012A (zh) 2020-12-15
US12246038B2 (en) 2025-03-11
JP2024105526A (ja) 2024-08-06
CN119770632A (zh) 2025-04-08
KR20210018295A (ko) 2021-02-17

Similar Documents

Publication Publication Date Title
US12246038B2 (en) Compositions for inducing an immune response
Madan et al. PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
US10682402B2 (en) MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
CN116437951A (zh) Sars-cov-2疫苗
KR20180094922A (ko) 암 치료 방법 및 조성물
Neukirch et al. Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice
IL309003A (en) Novel peptides, combination of peptides and scaffolds for use in immunothera-peutic treatment of various cancers
JP2016516742A (ja) ネコ用がんワクチン
Bhagat et al. CEA vaccines
Haq et al. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen
EP2572725B1 (en) MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
WO2014090265A1 (en) Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
TWI748349B (zh) 腫瘤特異性多肽序列及其應用
WO2024218165A1 (en) Hpv viral vector vaccine
KR20180059547A (ko) 항종양 조성물
TW202118773A (zh) 腫瘤特異性多肽序列及其應用
US20110104101A1 (en) Immunotherapy for Unresectable Pancreatic Cancer
JP2003522195A (ja) 肝細胞癌の治療のための方法及び組成物
HK40091839A (zh) 用於治疗癌症的方法和组合物
HK40091841A (zh) 用於治疗癌症的方法和组合物
AU2016201986B2 (en) MSI-specific Frameshift Peptides (FSP) for Prevention and Treatment of Cancer
CN115212300A (zh) 一种用于肝癌免疫治疗的组合物及其应用
HK40090579A (zh) 用於治疗癌症的方法和组合物
CA2799803C (en) Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
HODGE et al. CARCEVOEMBRYONIC ANTIGEN (CEA) AS A MODEL FOR IMMUNOTHERAPY USING RECOMBINANT VACCINES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19734251

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3097951

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020561892

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019270424

Country of ref document: AU

Date of ref document: 20190516

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20207036057

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019734251

Country of ref document: EP

Effective date: 20201216

WWR Wipo information: refused in national office

Ref document number: 1020207036057

Country of ref document: KR

WWC Wipo information: continuation of processing after refusal or withdrawal

Ref document number: 1020207036057

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 17055056

Country of ref document: US